Within the context of cisplatin chemotherapy of HNSCC, the upregulation of PD-L2 in response to cisplatin chemotherapy is a critical factor that must not be disregarded. The gene discussed is PDCD1LG2; the disease is head and neck squamous cell carcinoma.